NasdaqGM - Delayed Quote • USD
Amicus Therapeutics, Inc. (FOLD)
At close: 4:00 PM EDT
After hours: 5:43 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.07 | -0.02 | 0 | 0.39 |
| Low Estimate | -0.1 | -0.06 | -0.15 | 0.17 |
| High Estimate | -0.03 | 0.01 | 0.18 | 0.62 |
| Year Ago EPS | -0.18 | -0.15 | -0.51 | 0 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 11 |
| Avg. Estimate | 111.19M | 124.94M | 529M | 680.81M |
| Low Estimate | 107M | 120.75M | 511M | 618.98M |
| High Estimate | 114.8M | 129.46M | 548.49M | 798.27M |
| Year Ago Sales | 83.08M | 94.5M | 399.36M | 529M |
| Sales Growth (year/est) | 33.80% | 32.20% | 32.50% | 28.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.12 | -0.08 | -0.06 |
| EPS Actual | -0.18 | -0.15 | -0.07 | -0.11 |
| Difference | -0.03 | -0.03 | 0.01 | -0.05 |
| Surprise % | -20.00% | -25.00% | 12.50% | -83.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.07 | -0.02 | 0 | 0.39 |
| 7 Days Ago | -0.07 | -0.02 | 0 | 0.39 |
| 30 Days Ago | -0.06 | -0.02 | 0 | 0.4 |
| 60 Days Ago | -0.05 | 0 | 0.06 | 0.52 |
| 90 Days Ago | -0.05 | 0 | 0.06 | 0.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | FOLD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 61.10% | -- | -- | 0.40% |
| Next Qtr. | 86.70% | -- | -- | 9.90% |
| Current Year | 100.00% | -- | -- | 4.30% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | -147.10% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 3/18/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/29/2024 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 12/19/2023 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 11/9/2023 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 10/10/2023 |
| Maintains | JP Morgan: Overweight to Overweight | 9/29/2023 |
Related Tickers
PTCT PTC Therapeutics, Inc.
25.41
-2.16%
DYN Dyne Therapeutics, Inc.
25.44
+2.29%
PRTA Prothena Corporation plc
20.56
-3.43%
QURE uniQure N.V.
4.7500
-1.45%
ETNB 89bio, Inc.
8.92
-4.19%
RYTM Rhythm Pharmaceuticals, Inc.
40.00
+2.54%
TVTX Travere Therapeutics, Inc.
5.74
-1.88%
HALO Halozyme Therapeutics, Inc.
38.97
+0.67%
EWTX Edgewise Therapeutics, Inc.
15.65
+3.78%
IMTX Immatics N.V.
10.42
+2.26%